In the 1980s, inhaled corticosteroids (ICS) were adopted for use in chronic obstructive pulmonary disease (COPD) on the basis of their effectiveness in asthma, rather than on scientific evidence. In fact, evidence supporting their use in COPD is equivocal and their positioning in guidelines controversial. Despite this, evidence shows that ICS are being over-prescribed when they are not recommended. This program will review treatment objectives, the evidence and myths surrounding the use of ICS in COPD, better define which patients may benefit from ICS-containing therapy, and refocus on individualized treatment regimens.

RIVAL is the first head-to-head clinical trial to directly compare two of the most commonly used anti-vascular endothelial growth factor (VEGF) agents in patients with neovascular age-related macular degeneration (nAMD) using an identical treat-and-extend regimen. This program will review the primary and secondary endpoints of RIVAL, the results and other key features of the study.

This eXtract video features key information on the practical implementation of the recommended treatment algorithm for Chronic Spontaneous Urticaria (CSU), also known as chronic idiopathic urticaria. CSU is not a life-threatening condition but can impose meaningful reduction in quality of life even when present in mild to moderate severity.

This eXtract video features key information from the American College of Cardiology (ACC) Scientific Sessions & Expo. This quick tour with an expert focuses on data presented on the sub-analysis of the DECLARE-TIMI 58 trial, the most recent cardiovascular outcome trial (CVOT) conducted with sodium glucose co-transporter-2 (SGLT2) inhibitors.

This eXtract video features key information from the American Heart Association (AHA) Scientific Sessions. This quick tour with an expert focuses on data presented on the optimization of chronic heart failure therapies in-hospital and in the postdischarge phase with an emphasis on the PIONEER-HF and TRANSITION trials.

This eXtract video features key information from the American Academy of Ophthalmology (AAO) Annual Meeting. This quick tour with an expert focuses on data presented on Phase 3 studies (HAWK and HARRIER) which reaffirms the future role of this novel anti-VEGF therapy in the management of neovascular age-related macular degeneration (nAMD) in Canada.

This quick tour with an expert focuses on data presented on the phase III DECLARE-TIMI 58 trial, the most recent cardiovascular outcome trial (CVOT) conducted with sodium glucose co-transporter-2 (SGLT2) inhibitors.

Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. The GOLD guidelines recommend LAMAs, LABAs and their combination as the cornerstone of therapy for GOLD B, C and D patients. Many LABA/LAMA combinations have been studied in COPD; however, not all of them have demonstrated the same benefits. This program will review the recommendations for dual therapy and the evidence supporting these recommendations.

Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN), a type of progressive blood cancer. Patients diagnosed with PV have a characteristic over-proliferation of not only red blood cells, but also of white blood cells and platelets. The symptoms of PV are driven by a number of underlying mechanisms. Therapy to adequately control these mechanisms is key to relieving PV patients from their burdensome symptoms and disease-related complications. Therapies are available to manage blood counts and minimize the risk of complications, even in patients who are intolerant or resistant to conventional therapies. This program will review PV, its diagnosis and available treatment options.

Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. COPD is responsible for approximately 3 million deaths annually. The GOLD guidelines recommend a LAMA + LABA combination as initial therapy in patients with advanced disease (i.e., a predicted FEV1 of <30%). Triple therapy – a LAMA + LABA + an inhaled corticosteroid (ICS) – is recommended in patients who experience further exacerbation(s) on a LAMA + LABA combination. This program will review the recommendations for triple therapy and the evidence supporting these recommendations.